Yeah, I agree with your odds.
Re: label, I think approval for late-stage metastatic prostate cancer is basically a given. But the contention over labelling may be over whether it can be used early-stage, pre-treatment. There is significant impact on revenue between the two possible outcomes, but not disastrous. The broader label would eventually be granted after (presumably) more long-term safety data is provided.
Yeah, I agree with your odds. Re: label, I think approval for...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.65 |
Change
-0.250(1.09%) |
Mkt cap ! $7.565B | |||
| Open | High | Low | Value | Volume |
| $22.52 | $22.75 | $22.42 | $7.131M | 316.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 162 | $22.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.66 | 38 | 3 |
View Market Depth
| Last trade - 14.29pm 18/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |